Why the FT bought a majority stake in Endpoints News

Kerry Flynn of Axios spoke with Matt Fottrell, vice president of the Financial Times in the U.S. and managing director of FT Specialist, about its majority stake purchase in biotech news site Endpoints News.

Flynn writes, “Speaking from the FT’s New York office in the west side of Soho, Fottrell says the deal with Endpoints made sense given the publication’s editorial mission aligned with its own.

“‘The biopharma sector’s a multitrillion-dollar industry. It’s highly regulated. It’s incredibly competitive. There’s always deals taking place … and they are news hungry,’ Fottrell says.
‘Broadly speaking, I like businesses where there’s a prize for winning and a penalty for losing,’ he adds. ‘That makes [people] more likely to subscribe.'”

To read more, go here.

Chris Roush

Chris Roush was the dean of the School of Communications at Quinnipiac University in Hamden, Connecticut. He was previously Walter E. Hussman Sr. Distinguished Professor in business journalism at UNC-Chapel Hill. He is a former business journalist for Bloomberg News, Businessweek, The Atlanta Journal-Constitution, The Tampa Tribune and the Sarasota Herald-Tribune. He is the author of the leading business reporting textbook "Show me the Money: Writing Business and Economics Stories for Mass Communication" and "Thinking Things Over," a biography of former Wall Street Journal editor Vermont Royster.